Jeffrey M Leiden

Director Jeffrey Leiden makes first open-market purchase in three years amid cluster of insider buying; breaks pattern of prior sales.

Jeffrey Leiden, a company director, made his first open-market stock purchase in over three years, acquiring shares while the stock is trading near its lowest levels since the recent IPO. This marks a notable shift: Leiden's prior activity in the company consisted entirely of sales and stock-based compensation transactions, making this purchase a regime change from net seller to buyer. The timing coincides with at least three other insiders buying within the same two-week window, creating a cluster pattern that suggests multiple board and executive members are deploying capital at current price levels. Leiden's historical record on prior sales shows mixed outcomes, though the vast majority of his prior sells were followed by stock appreciation—meaning his prior sales had poor timing. This current purchase at newly-public price levels, combined with the broader insider buying cluster, warrants attention as a potential accumulation signal during an early period in the company's public trading history.

VRTX Executive Chairman Leiden sells 63,781 shares for $28.7M in 12 transactions at blended $449.20, reducing stake 72.6%

Jeffrey M. Leiden, Executive Chairman of Vertex Pharmaceuticals, executed 12 separate sales on 2025-12-03 totaling 63,781 shares for $28,650,336.65, at a blended average price of $449.20. This sale reduced his holdings from 87,808 shares to 24,027 shares, representing a 72.6% reduction in his position. The stock is currently trading at $455.48, only 1.4% above his blended sale prices, and the company reported recent quarterly revenue of $3,076,400,000.00 and net income of $1,082,900,000.00 with 11.7% annual revenue growth. The scale and structure of this divestiture—a near-total exit across multiple price points on a single day—warrants investor scrutiny regarding Leiden's confidence in the business outlook, particularly given the company's transition to profitability and strong growth trajectory.

Executive Chairman Leiden sells 73,292 shares ($32.3M) across two days, reducing holdings by 75.3%

Jeffrey M Leiden, Executive Chairman of Vertex Pharmaceuticals, executed 5 separate sales totaling 73,292 shares for $32,292,319.86 on November 13-14, 2025, at prices ranging from $440.22 to $442.00 (blended average $440.60). This disposition reduced his holdings from 97,318 shares to 24,026 shares, a 75.3% reduction. The transaction occurred at prices $6.58 above the current price of $434.02, indicating sales executed near the 52-week high of $513.76 (though currently 15.5% below that peak). His prior VRTX sales (5 trades since 2024) show inconsistent timing outcomes: only 1 of 5 prior sales at this ticker resulted in negative 90-day returns (well-timed), while his cross-ticker track record across 16 sells shows a 37.50% well-timed rate with an average 90-day return of +1.4%. The substantial reduction in the Executive Chairman's stake merits investor attention given the concentration of sales within a two-day window and the magnitude of the position reduction.

Leiden (Exec Chair) sold 3,784 VRTX shares at $499.00; post-sale holdings 10.0K shares.

On 2024-08-30, Jeffrey M Leiden, Executive Chairman of Vertex Pharmaceuticals, sold 3,784 shares at $499.00, reducing his holdings by 27.5% to 10.0K shares and realizing $1.9M in proceeds. Leiden's cross-ticker track record across 15 prior open-market sales shows an average 90-day return of +1.9% with a 33.33% well-timed rate, but his prior sales at VRTX specifically (5 trades across February 2024) were all poorly timed, with 0 of 5 showing declines after 90 days. The stock is currently at $478.57, down 5.4% from the 52-week high of $505.78 and trading near the upper end of its annual range, while the company reported a $-3.6B net income in its latest quarter despite +10.5% annual revenue growth. The significant reduction in Leiden's holdings warrants observation against the stock's current valuation multiple (P/E of 34.06) and historical pattern of post-sale price appreciation at this ticker.